NCT05903170Recruiting
Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation
A Randomised Trial of Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 1 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to compare the efficacy of a maximum output shock for cardioverting atrial fibrillation between two commonly used defibrillators in New Zealand . These machines have different maximum energy outputs, and to date no head-to-head comparison cardioverting atrial fibrillation between the two has been undertaken. The main question it aims to answer is whether either device is more likely to cardiovert patients referred for atrial fibrillation. Participants will be randomized to undergo cardioversion with one of two defibrillators at either 200J or 360J. Participants in each arm will undergo up to three shocks at the energy-level to which they have been randomized, using a standardized procedure. For participants randomized to the lower energy level who fail to return to normal rhythm after three shocks, they will be given a fourth shock at the higher energy level. All participants will then be asked to undertake a blood test the day following the cardioversion, and receive a follow up phone call. These are to ensure there is no difference in the safety of the procedure between the two energy levels. It is worth noting that these two components of the study (the blood test and phone call) are the only additional time commitment that is expected to be involved if you choose to participate in the study.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 25 May 2023
- Start date
- 1 Aug 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Wellington Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT05903170
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Aug 2025 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Implantable cardiac device (PPM or ICD)
Other
- Contraindication to anticoagulation
- Atrial flutter
- Emergent cardioversion
- Unable to consent to cardioversion and/or study participation
- Pregnancy
Who the study is looking for
- Age \>18
- Patients undergoing either elective outpatient or non-emergent inpatient cardioversion for atrial fibrillation
- Eligible for anticoagulation
- Reliably anticoagulated for ≥three weeks prior to cardioversion, AF onset within 48hrs of cardioversion, or left atrial thrombus excluded on transoesophageal echocardiogram
- Able to consent to cardioversion, and study participation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wellington Regional Hospital Coordinator of this site? Confirm its status | Wellington | New Zealand | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.